About Wegovy HD (semaglutide) injection 7.2 mg The FDA approval of Wegovy HD is based on the results of the STEP UP program, which included the phase 3 STEP UP clinical trial, which was a 72-week randomized, double-blinded, placebo-controlled and active-controlled superiority trial designed to evaluate the efficacy and safety of once-weekly semaglutide injection 7.2 mg compared to semaglutide injection 2.4 mg and placebo as an adjunct to lifestyle intervention
These results suggest that GLP1R agonists in combination with a calcitonin receptor agonist, is able to show even larger decreases in body weight than typical GLP1R agonists, within a shorter time and with a more favourable side effect profile
Reported across doses, often related to reduced food intake during the stepping-up phase
Your provider will ask about your weight history in detail
During Your Treatment Just 2 minutes from Bluewater Shopping Centre, youll find nothing but peace and quiet at our clinic located in a discrete purpose built clinic